RenovoRx, Inc. — Form 8-K/A
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 68/100
What the filing says
RenovoRx reported Q2 2026 revenue of $909K (up 61% QoQ, 115% YoY vs Q2 2025's $422K); raised full-year 2026 guidance from $3.0-4.0M to $3.75-4.25M (representing 241-286% YoY growth vs 2025's $1.1M). Active commercial cancer centers grew from 16 to 21 (+31%); Phase III TIGeR-PaC trial reached full enrollment with completion expected H1 2027 and topline data in H2 2027. Cash position $9.5M as of June 30, 2026; management targets cash-flow break-even at ~$5M quarterly run-rate, anticipated Q4 2027. First physician-driven use of RenovoCath in sarcoma (beyond pancreatic cancer) occurred in August 2026.
Why this rating
Strong commercial momentum (61% QoQ growth, guidance raise) and clinical progress (full enrollment) are material for a $26.6M-market-cap company. However, still pre-breakeven with $2.9M quarterly losses; cash runway to H2 2027 presents refinancing risk if growth stalls.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.